balance equationreview2025-06-30
Difference 3581415 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$0
Fiscal year ended 2026-06-30Operating income
-$7.56M
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30Moleculin Biotech, Inc. (MBRX) reported revenue of $0 and net income of -$7.64M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Moleculin Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$7.56M | -$7.87M | -$7.53M | -$5.91M | -$5.72M | -$5.94M | -$6.64M | -$7.14M | -$6.18M | -$6.68M |
| Net income | -$7.64M | -$12.84M | $15.55M | -$25.40M | -$17.81M | -$5.90M | -$6.58M | -$7.02M | -$6.02M | -$6.42M |
| Research & development | $5.45M | $5.38M | $5.12M | $3.74M | $3.60M | $3.44M | $4.46M | $4.93M | $4.09M | $4.25M |
| Weighted-average diluted shares | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Diluted EPS | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $2.10M | $2.49M | $2.41M | $2.15M | $2.09M | $2.48M | $2.16M | $2.17M | $2.06M | $2.39M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.26M | $10.32M | $8.88M | $6.70M | $7.56M | $7.72M | $4.28M | $9.40M | $10.84M | $16.82M |
| Total assets | $21.09M | $23.36M | $22.13M | $20.35M | $21.59M | $21.01M | $16.92M | $23.39M | $25.58M | $30.84M |
| Current assets | $8.72M | $10.96M | $9.69M | $7.88M | $9.08M | $9.34M | $5.19M | $11.61M | $13.73M | $18.96M |
| Total liabilities | $9.50M | $8.18M | $7.12M | $47.27M | $25.18M | $7.22M | $5.72M | $15.92M | $7.87M | $9.26M |
| Current liabilities | $9.31M | $7.96M | $6.85M | $5.68M | $7.91M | $6.90M | $5.36M | $5.59M | $5.75M | $5.41M |
| Total equity incl. NCI | $11.59M | $15.18M | $15.01M | -$26.92M | -$3.58K | $13.79M | $11.21M | $17.41M | $19.41M | $24.99M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $4.34M | $4.57M | $3.51M | $2.12M | $3.72M | $2.71M | $2.03M | $2.55M | $2.83M | $2.10M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.66M | -$6.11M | -$5.37M | -$7.22M | -$5.58M | -$4.56M | -$5.08M | -$6.11M | -$5.95M | -$6.72M |
| Capital expenditures | Unavailable | Unavailable | $0 | $0 | $0 | $0 | $0 | $0 | $13.00K | $0 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$13.00K | $0 |
| Financing cash flow | $3.61M | $7.61M | $7.49M | $6.38M | $5.42M | $8.00M | $1.00K | $4.66M | -$25.00K | $0 |
| Net change in cash | -$3.06M | $1.44M | $2.18M | -$854.00K | -$159.00K | $3.44M | -$5.13M | -$1.44M | -$5.98M | -$6.73M |
| Stock-based compensation | $436.00K | $380.00K | $459.00K | $303.00K | $417.00K | $485.00K | $427.00K | $353.00K | $453.00K | $493.00K |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $8.00K | $8.00K | $9.00K | $21.00K | $29.00K | $31.00K | $31.00K | $31.00K | $31.00K | $32.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | -$5.37M | -$7.22M | Unavailable | Unavailable | -$5.08M | -$6.11M | -$5.96M | -$6.72M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current ratio | 0.94x | 1.38x | 1.41x | 1.39x | 1.15x | 1.35x | 0.97x | 2.08x | 2.39x | 3.51x |
| Revenue YoY growth | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MBRX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing
Reconciliation checks needing review
5 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2024-09-30
Difference 9932000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-06-30
Difference 1704000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-03-31
Difference 3400000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2023-12-31
Difference 4855000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.